HanchorBio Inc. is a clinical-stage biotechnology company developing next-generation biologic therapeutics, including bi- and multi-functional fusion proteins and other multispecific antibody constructs, to treat cancer and autoimmune diseases. The company applies protein engineering and immunology expertise to design drug candidates that modulate multiple disease pathways within a single molecule.
HanchorBio advances programs from discovery through early clinical evaluation and collaborates with specialized partners for analytical development, formulation, and GMP manufacturing. Its work spans cell line and process development, bioassay design, and drug product development typical of modern biologics R&D. By targeting high-unmet-need indications with modular, multi-target biologics, HanchorBio contributes to the biopharmaceutical landscape at the intersection of protein science and immunotherapy.
